603127 Joinn Laboratories
- 18.05
- +1.64+9.99%
Joinn Laboratories News
Revenues Not Telling The Story For Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) After Shares Rise 28%
JOINN: 2024 Interim Report
HK stocks anomaly | CRO concept stocks continue to rise, hindered by the enactment of the Biosecurity Law, top companies' investment sentiment is expected to marginally improve.
The CRO concept stocks continue to rise. As of the time of publication, Tigermed (03347) rose by 9.28%, to 31.2 Hong Kong dollars; Pharmaron (03759) rose by 4.85%, to 11.24 Hong Kong dollars; and Joinn Laboratories (06127) rose by 4.8%, to 7.64 Hong Kong dollars.
Joinn Laboratories(China)Co.Ltd Insiders Sell CN¥92m Of Stock, Possibly Signalling Caution
The CRO sector is showing strong upward momentum. Pharmaron (03759) rose by 13.48%. Institutions are bullish on the leading domestic clinical CRO company.
Jingu financial news | The CRO sector is strong, with Pharmaron (03759) up 13.48%, WuXi AppTec (02359) up 11.96%, WuXi Biologics (02269) up 11.06%, Tigermed (03347) up 7.14%, Asymchem Laboratories (06821) up 6.92%, Joinn Laboratories (06127) up 5%. Guotai Junan Securities stated that with the US interest rate cut and the continued significant decline in profits of domestic innovative companies, the main reason is the increase in operating expenses. With the support of the pharmaceutical industry, CXO companies' operating performance is expected to gradually bottom out and rebound, and the valuation will
Joinn Laboratories (06127.HK) spent 0.8413 million yuan on September 18 to repurchase 0.063 million shares of A shares.
Joinn Laboratories (06127.HK) announced on September 19 that it will repurchase 0.063 million A-shares for a total of CNY 0.8413 million on September 18, 2024, at a repurchase price of CNY 13.3-13.43 per share.
Joinn Laboratories (06127.HK) spent 2.79 million yuan on September 10th repurchasing 0.2095 million shares of A shares.
On September 10th, Joinn Laboratories (06127.HK) announced that it has repurchased 0.2095 million shares of A shares at a cost of 2.79 million RMB.
Nomura Adjusts Joinn Laboratories (China)'s Price Target to 12.60 Yuan From 12.27 Yuan, Keeps at Neutral
Maintaining Buy Rating: JOINN Laboratories' Turnaround and Expansion Signal Strong Growth Potential
Hong Kong stocks abnormal | Joinn Laboratories (06127) fell more than 7% in the afternoon, turning from profit to a loss of 0.17 billion yuan in the first half of the year, with a year-on-year gross profit decline.
Joinn Laboratories (06127) fell more than 7% in the afternoon. As of the time of writing, it was down 7.21% at HKD 6.56, with a turnover of HKD 7.8144 million.
Joinn Laboratories(China) Swings to Loss in H1; Shares Slide Over 3%
Joinn Laboratories (06127) plans to cancel approximately 0.8189 million shares of stock options.
Joinn Laboratories (06127) announced that according to the company's 2020 stock options incentive plan (draft) and...
Joinn Laboratories (06127) plans to increase its capital by 30 million US dollars to Joinn (California) New Drug Research Center.
joinn laboratories (06127) announced that, based on strategic needs and business expansion requirements, the board of directors of the company has agreed to use H ...
Zhaoyan New Pharmaceutical 2024 Semi-Annual Report
Summary of Zhaoyan Pharmaceutical\'s 2024 Semi-Annual Report
JOINN Labs Reports Significant Interim Losses
Express News | Joinn Laboratories China - Hy Rev RMB849.4 Mln
Express News | Joinn Laboratories China - Hy Loss Attributable RMB169.7 Mln
JOINN: ANNOUNCEMENT OF INTERIM RESULTSFOR THE SIX MONTHS ENDED 30 JUNE 2024
Joinn Laboratories released its interim performance, with revenue of 849 million yuan and a net loss attributable to the parent company of 170 million yuan, which turned from profit to loss year-on-year.
Joinn Laboratories (06127) announced the interim results for the year 2024, with revenue of 0.849 billion yuan (RMB, the same below) during the period, a decrease of 16.08% year-on-year; net loss attributable to shareholders of the listed company was 0.17 billion yuan, while net income for the same period last year was 90.6272 million yuan; basic loss per share was 0.23 yuan.
Analysis
Price Target
No Data
No Data